Epitopes described in "Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus."

Article Authors:Edward N van den Brink; Jan Ter Meulen; Freek Cox; Mandy A C Jongeneelen; Alexandra Thijsse; Mark Throsby; Wilfred E Marissen; Pauline M L Rood; Alexander B H Bakker; Hans R Gelderblom; Byron E Martina; Albert D M E Osterhaus; Wolfgang Preiser; Hans Wilhelm Doerr; John de Kruif; Jaap Goudsmit
Article Title:Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.
Reference Detail
Reference ID:652
Abstract:Human monoclonal antibodies (MAbs) were selected from semisynthetic antibody phage display libraries by using whole irradiated severe acute respiratory syndrome (SARS) coronavirus (CoV) virions as target. We identified eight human MAbs binding to virus and infected cells, six of which could be mapped to two SARS-CoV structural proteins: the nucleocapsid (N) and spike (S) proteins. Two MAbs reacted with N protein. One of the N protein MAbs recognized a linear epitope conserved between all published human and animal SARS-CoV isolates, and the other bound to a nonlinear N epitope. These two N MAbs did not compete for binding to SARS-CoV. Four MAbs reacted with the S glycoprotein, and three of these MAbs neutralized SARS-CoV in vitro. All three neutralizing anti-S MAbs bound a recombinant S1 fragment comprising residues 318 to 510, a region previously identified as the SARS-CoV S receptor binding domain; the nonneutralizing MAb did not. Two strongly neutralizing anti-S1 MAbs blocked the binding of a recombinant S fragment (residues 1 to 565) to SARS-CoV-susceptible Vero cells completely, whereas a poorly neutralizing S1 MAb blocked binding only partially. The MAb ability to block S1-receptor binding and the level of neutralization of the two strongly neutralizing S1 MAbs correlated with the binding affinity to the S1 domain. Finally, epitope mapping, using recombinant S fragments (residues 318 to 510) containing naturally occurring mutations, revealed the importance of residue N479 for the binding of the most potent neutralizing MAb, CR3014. The complete set of SARS-CoV MAbs described here may be useful for diagnosis, chemoprophylaxis, and therapy of SARS-CoV infection and disease.
Affiliations:Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands.
Reference Type:Literature
PubMed ID:15650189
Journal:J Virol
Journal Volume:79
Article Pages:1635-44
Journal ISSN:1098-5514
Article Chemical List:Antibodies, Monoclonal;Antibodies, Viral;Membrane Glycoproteins;Nucleocapsid Proteins;S protein, severe acute respiratory syndrome coronavirus;Spike Glycoprotein, Coronavirus;Viral Envelope Proteins;nucleocapsid protein, Coronavirus
Article MeSH List:Amino Acid Sequence; Animals; Antibodies, Monoclonal(chemistry; genetics; immunology); Antibodies, Viral(chemistry; genetics; immunology); Antibody Specificity; Binding Sites; Cercopithecus aethiops; Epitope Mapping; Humans; Membrane Glycoproteins(immunology); Molecular Sequence Data; Neutralization Tests; Nucleocapsid Proteins(immunology); SARS Virus(immunology); Spike Glycoprotein, Coronavirus; Vero Cells; Viral Envelope Proteins(immunology)
Curation Last Updated:2015-06-18 20:01:30